• Corpus ID: 29355850

The PossibiliTy of encouraging innovaTion and comPeTiTion by erwin a . blacksTone

@inproceedings{Fuhr2015ThePO,
  title={The PossibiliTy of encouraging innovaTion and comPeTiTion by erwin a . blacksTone},
  author={Joseph P. Jr. Fuhr},
  year={2015}
}

References

SHOWING 1-5 OF 5 REFERENCES
Understanding and Incentivizing Biosimilars
TLDR
The Biosimilars Act and the draft guidances recently released by the FDA are analyzed to identify areas of uncertainty and other aspects of the current regime that create disincentives for the development of biosimilars, as well as suggesting improvements.
Schondeemeyer, Rx Price Watch Case Study: Efforts to Reduce Impact of Generic Competition for Lipitor
  • AARP Public Policy Institute, Insight on the Issues
  • 2013
Lybecker, When Patents Aren’t Enough: Why Patents Necessitate Data Exclusivity Protection
  • William Mitchell L. Rev
  • 2014
The Future of Competition in the Biologics Market
  • Temple J. Sci. Technol. Envir. L
  • 2012
Celltrion’s Opposition to Janssen’s Motion to Dismiss for Lack of Subject Matter Jurisdiction
  • Case No. 1:14cv-11613 (D. Mass., July
  • 2014